NASDAQ:HSDT

Helius Medical Technologies Competitors

$16.90

-0.22 (-1.29 %)

(As of 04/16/2021 12:00 AM ET)

Add

Compare

Today's Range

$16.55

Now: $16.90▼

$17.06

50-Day Range

$12.41

MA: $15.40▼

$18.45

52-Week Range

$9.45

Now: $16.90▼

$34.00

Volume24,518 shs

Average Volume134,469 shs

Market Capitalization$39.06 million

P/E RatioN/A

Dividend YieldN/A

Beta0.72

Helius Medical Technologies (NASDAQ:HSDT) Vs. MDT, VAR, MASI, LIVN, CNMD, and INMD

Should you be buying HSDT stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Helius Medical Technologies, including Medtronic (MDT), Varian Medical Systems (VAR), Masimo (MASI), LivaNova (LIVN), CONMED (CNMD), and InMode (INMD).

Helius Medical Technologies vs. Medtronic Stock

Medtronic (NYSE:MDT) and Helius Medical Technologies (NASDAQ:HSDT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Medtronic and Helius Medical Technologies' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medtronic	$28.91 billion	5.87	$4.79 billion	$4.59	27.43
Helius Medical Technologies	$1.50 million	26.04	$-9,780,000.00	($12.94)	-1.31

Medtronic has higher revenue and earnings than Helius Medical Technologies. Helius Medical Technologies is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

79.2% of Medtronic shares are owned by institutional investors. 0.5% of Medtronic shares are owned by company insiders. Comparatively, 17.4% of Helius Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Medtronic and Helius Medical Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medtronic	0	3	19	1	2.91
Helius Medical Technologies	0	1	2	0	2.67

Medtronic presently has a consensus price target of $125.3333, suggesting a potential downside of 0.46%. Helius Medical Technologies has a consensus price target of $20.00, suggesting a potential upside of 18.34%. Given Helius Medical Technologies' higher probable upside, analysts plainly believe Helius Medical Technologies is more favorable than Medtronic.

Profitability

This table compares Medtronic and Helius Medical Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medtronic	12.69%	9.71%	5.30%
Helius Medical Technologies	-2,716.85%	-328.07%	-201.87%

Risk & Volatility

Medtronic has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Helius Medical Technologies has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Summary

Medtronic beats Helius Medical Technologies on 11 of the 15 factors compared between the two stocks.

Helius Medical Technologies vs. Varian Medical Systems Stock

Helius Medical Technologies (NASDAQ:HSDT) and Varian Medical Systems (NYSE:VAR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Profitability

This table compares Helius Medical Technologies and Varian Medical Systems' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Helius Medical Technologies	-2,716.85%	-328.07%	-201.87%
Varian Medical Systems	8.50%	18.45%	8.08%

Institutional and Insider Ownership

87.0% of Varian Medical Systems shares are owned by institutional investors. 17.4% of Helius Medical Technologies shares are owned by insiders. Comparatively, 0.8% of Varian Medical Systems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Helius Medical Technologies and Varian Medical Systems, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Helius Medical Technologies	0	1	2	0	2.67
Varian Medical Systems	3	5	0	0	1.63

Helius Medical Technologies currently has a consensus target price of $20.00, suggesting a potential upside of 18.34%. Varian Medical Systems has a consensus target price of $159.3571, suggesting a potential downside of 10.00%. Given Helius Medical Technologies' stronger consensus rating and higher probable upside, research analysts clearly believe Helius Medical Technologies is more favorable than Varian Medical Systems.

Earnings and Valuation

This table compares Helius Medical Technologies and Varian Medical Systems' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Helius Medical Technologies	$1.50 million	26.04	$-9,780,000.00	($12.94)	-1.31
Varian Medical Systems	$3.17 billion	5.13	$269.20 million	$3.91	45.29

Varian Medical Systems has higher revenue and earnings than Helius Medical Technologies. Helius Medical Technologies is trading at a lower price-to-earnings ratio than Varian Medical Systems, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Helius Medical Technologies has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Comparatively, Varian Medical Systems has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.

Summary

Varian Medical Systems beats Helius Medical Technologies on 9 of the 14 factors compared between the two stocks.

Helius Medical Technologies vs. Masimo Stock

Masimo (NASDAQ:MASI) and Helius Medical Technologies (NASDAQ:HSDT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Earnings and Valuation

This table compares Masimo and Helius Medical Technologies' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Masimo	$937.84 million	14.48	$196.22 million	$3.22	76.32
Helius Medical Technologies	$1.50 million	26.04	$-9,780,000.00	($12.94)	-1.31

Masimo has higher revenue and earnings than Helius Medical Technologies. Helius Medical Technologies is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Masimo and Helius Medical Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Masimo	20.30%	15.75%	13.12%
Helius Medical Technologies	-2,716.85%	-328.07%	-201.87%

Institutional and Insider Ownership

81.6% of Masimo shares are owned by institutional investors. 11.5% of Masimo shares are owned by company insiders. Comparatively, 17.4% of Helius Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Masimo and Helius Medical Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Masimo	0	2	5	0	2.71
Helius Medical Technologies	0	1	2	0	2.67

Masimo presently has a consensus target price of $272.20, suggesting a potential upside of 10.77%. Helius Medical Technologies has a consensus target price of $20.00, suggesting a potential upside of 18.34%. Given Helius Medical Technologies' higher possible upside, analysts clearly believe Helius Medical Technologies is more favorable than Masimo.

Risk and Volatility

Masimo has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Helius Medical Technologies has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Summary

Masimo beats Helius Medical Technologies on 11 of the 14 factors compared between the two stocks.

Helius Medical Technologies vs. LivaNova Stock

LivaNova (NASDAQ:LIVN) and Helius Medical Technologies (NASDAQ:HSDT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings.

Volatility and Risk

LivaNova has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Helius Medical Technologies has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Profitability

This table compares LivaNova and Helius Medical Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LivaNova	-21.88%	5.55%	3.07%
Helius Medical Technologies	-2,716.85%	-328.07%	-201.87%

Earnings & Valuation

This table compares LivaNova and Helius Medical Technologies' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.08 billion	3.65	$-155,180,000.00	$3.08	26.41
Helius Medical Technologies	$1.50 million	26.04	$-9,780,000.00	($12.94)	-1.31

Helius Medical Technologies has lower revenue, but higher earnings than LivaNova. Helius Medical Technologies is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for LivaNova and Helius Medical Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0	4	2	0	2.33
Helius Medical Technologies	0	1	2	0	2.67

LivaNova presently has a consensus target price of $69.3333, suggesting a potential downside of 14.76%. Helius Medical Technologies has a consensus target price of $20.00, suggesting a potential upside of 18.34%. Given Helius Medical Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Helius Medical Technologies is more favorable than LivaNova.

Institutional & Insider Ownership

89.1% of LivaNova shares are owned by institutional investors. 0.5% of LivaNova shares are owned by insiders. Comparatively, 17.4% of Helius Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

LivaNova beats Helius Medical Technologies on 7 of the 13 factors compared between the two stocks.

Helius Medical Technologies vs. CONMED Stock

Helius Medical Technologies (NASDAQ:HSDT) and CONMED (NYSE:CNMD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Helius Medical Technologies and CONMED, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Helius Medical Technologies	0	1	2	0	2.67
CONMED	0	2	3	0	2.60

Helius Medical Technologies presently has a consensus price target of $20.00, suggesting a potential upside of 18.34%. CONMED has a consensus price target of $103.25, suggesting a potential downside of 20.71%. Given Helius Medical Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Helius Medical Technologies is more favorable than CONMED.

Profitability

This table compares Helius Medical Technologies and CONMED's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Helius Medical Technologies	-2,716.85%	-328.07%	-201.87%
CONMED	0.04%	9.48%	3.75%

Valuation and Earnings

This table compares Helius Medical Technologies and CONMED's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Helius Medical Technologies	$1.50 million	26.04	$-9,780,000.00	($12.94)	-1.31
CONMED	$955.10 million	3.96	$28.62 million	$2.64	49.32

CONMED has higher revenue and earnings than Helius Medical Technologies. Helius Medical Technologies is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Helius Medical Technologies has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, CONMED has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500.

Summary

CONMED beats Helius Medical Technologies on 8 of the 12 factors compared between the two stocks.

Helius Medical Technologies vs. InMode Stock

InMode (NASDAQ:INMD) and Helius Medical Technologies (NASDAQ:HSDT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for InMode and Helius Medical Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	0	0	4	0	3.00
Helius Medical Technologies	0	1	2	0	2.67

InMode currently has a consensus price target of $71.50, suggesting a potential downside of 18.11%. Helius Medical Technologies has a consensus price target of $20.00, suggesting a potential upside of 18.34%. Given Helius Medical Technologies' higher probable upside, analysts clearly believe Helius Medical Technologies is more favorable than InMode.

Profitability

This table compares InMode and Helius Medical Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InMode	32.57%	28.56%	24.14%
Helius Medical Technologies	-2,716.85%	-328.07%	-201.87%

Institutional and Insider Ownership

35.7% of InMode shares are held by institutional investors. 17.4% of Helius Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares InMode and Helius Medical Technologies' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$156.36 million	17.85	$61.15 million	$1.60	54.57
Helius Medical Technologies	$1.50 million	26.04	$-9,780,000.00	($12.94)	-1.31

InMode has higher revenue and earnings than Helius Medical Technologies. Helius Medical Technologies is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

InMode has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. Comparatively, Helius Medical Technologies has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.

Summary

InMode beats Helius Medical Technologies on 11 of the 14 factors compared between the two stocks.